Introduction {#s1}
============

Asthma affects over 17.5 million adults in North America and its prevalence continues to rise, as evidenced by the 12.3% relative increase from 2001 (7.3%) to 2009 (8.2%).[@R1] Worldwide, asthma prevalence ranges from low (underdeveloped countries) to high (developed countries).[@R2] Asthma is predominantly a chronic disease that can be controlled with appropriate pharmacological and non-pharmacological interventions;[@R3] however, exacerbations do not always respond to standard or additional treatment options, leading to urgent visits to health providers, admissions to hospital and, in severe and rare cases, death.[@R4] In the USA, patients with exacerbations had significantly higher asthma-related healthcare costs: \$1740 over 1 year compared with \$847 for asthmatics without exacerbations.[@R5] While patients with acute asthma often seek care in the emergency department (ED),[@R6] most are successfully treated and subsequently discharged;[@R7] [@R8] only 6--12% of adult patients presenting to the ED with an exacerbation of asthma will be admitted.[@R8] [@R9]

The understanding and management of acute asthma have advanced considerably in recent years. Current evidence-based guidelines (National Asthma Education and Prevention Plan (NAEPP),[@R10] Global Initiative for Asthma (GINA),[@R11] and Canadian Thoracic Society (CTS)[@R12]) suggest that early treatment with short-acting β~2~-agonists, inhaled short-acting anticholinergic agents and systemic corticosteroids (SCS) will reduce hospitalisations. On ED discharge, SCS are recommended,[@R13] [@R14] and further studies suggest that prescribing inhaled corticosteroids (ICS) at discharge can reduce relapse following discharge at least in adult patients.[@R15] ICS in combination with long-acting β-agonists (ICS/LABA) are more effective than ICS monotherapy in patients with persistent asthma, with the number needed to treat of 19 to prevent one exacerbation.[@R18] On the other hand, the impact of non-pharmacological interventions (ie, ED-based educational strategies) on relapses remains unclear.[@R19] [@R20]

While considerable improvement in the management of acute asthma should lead to better outcomes over time, practice variation does exist and many patients presenting to EDs do not always receive evidence-based treatment.[@R13] Moreover, what works in certain settings may not be applicable to others. Despite the dissemination of effective interventions for the prevention of relapses after asthma exacerbations, these outcomes still occur, affect the quality of life[@R21] of patients with asthma and represent significant costs to the healthcare system.[@R5]

A number of studies have examined factors associated with relapse outcomes in adults after ED discharge.[@R22] Notwithstanding this research, there remains a relative paucity of literature attempting to compile the existing information to influence management. The objective of this study was to summarise the evidence regarding relapses and factors associated with increased relapse in patients discharged from EDs after being treated for asthma exacerbations.

Methods {#s2}
=======

Protocol {#s2a}
--------

A study protocol was developed a priori to define the objectives, search strategy, eligibility criteria, outcomes of interest, the process for abstracting and synthesising information from eligible studies, and the methods for data analysis. The systematic review conforms to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered with International prospective register of systematic reviews (PROSPERO) (CRD42015023844). No ethics approval was required.

Literature search {#s2b}
-----------------

Comprehensive searches of seven electronic databases (Medline, EMBASE, Cochrane Library, CINAHL, SCOPUS, LILAC, and ProQuest Dissertations and Theses) were conducted from their inception to June 2015. The search strategy was designed by a health sciences librarian (LD) and comprised controlled vocabulary and keywords. The search used a slightly modified version of an 'emergency room' search filter[@R27] (see online [supplementary appendix A](#SM1){ref-type="supplementary-material"}; complete search strategy is available on request).
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References were manually selected from the first 10 pages of Google Scholar. In addition, proceedings from important Canadian Association of Emergency Physicians (CAEP) and US Society for Academic Emergency Medicine (SAEM) conferences held between 2005 and 2015 that involved research presentations were hand-searched. No limits were applied on the basis of date, study design, language or publication status.

Study selection {#s2c}
---------------

The review included studies assessing the proportion of adult patients (or adults and children with ≥80% of the study population being ≥17 years of age) relapsing after receiving treatment in the ED for an asthma exacerbation. Relapse and variables significantly associated with relapse after multivariable modelling were the primary outcomes presented in this review. To be included as factors associated with relapse, studies must have conducted adjusted analyses. Relapse was defined as an urgent visit to any ED, clinic or physician office for worsening asthma symptoms within 4 weeks of the initial ED visit. Secondary outcomes included time between ED discharge and relapse, and medical management received in the ED.

Two reviewers (JH, NA) independently screened the titles and abstracts of studies identified by the literature search. Articles initially deemed relevant and those whose abstracts and titles provided insufficient information were retrieved and independently reviewed (JH, NA) to determine study eligibility. Disagreements were discussed and resolved with a third party (CVR).

Data extraction and quality assessment {#s2d}
--------------------------------------

Information on patients, methods, interventions and outcomes was extracted from the original reports onto standardised data collection forms independently by two authors (JH, NA). Information was cross-referenced to ensure accuracy. If necessary, authors were contacted to clarify information or provide unpublished data.

Assessment of study quality {#s2e}
---------------------------

Two reviewers (JH, NA) independently evaluated each of the included studies using the Newcastle--Ottawa Scale (NOS) for observational studies and the Cochrane Risk of Bias Tool (RoB), a quality assessment tool used to assess controlled clinical trials (CCT) for risk of bias. Any discrepancies were discussed with a third party (CVR). Information on study quality will help authors evaluate the validity of the findings.

Data synthesis and statistical analysis {#s2f}
---------------------------------------

Characteristics of the included studies were summarised using descriptive statistics (eg, numbers with proportions for dichotomous variables and means with standard deviations (±SD) or medians with interquartile ranges (IQR) for continuous variables). An evidence table was constructed to report information on each article\'s source, year of publication, country of origin, study design, sample size and outcomes. Analyses were focused on the proportion of relapses; a subgroup analysis by the end of data collection (year) was completed. Inter-rater agreement between the two reviewers evaluating study quality using the NOS was measured using the κ statistic. Effect estimates from individual studies were presented as adjusted ORs (aORs) with 95% CIs when possible. Owing to the variations in models used to generate aORs and in the factors reported, results were not pooled in a traditional meta-analysis. Finally, factors associated with relapse at a statistically significant level (p\<0.05) were summarised in a table. Figures were generated using GraphPad Prism V.6.07 for Windows (GraphPad Software, La Jolla, California, USA).

Results {#s3}
=======

Search results {#s3a}
--------------

After combining the results of the electronic search strategy with the grey literature, removing duplicates, screening for titles and abstracts, and reviewing full-text articles, 10 studies were included in the review ([figure 1](#BMJRESP2016000169F1){ref-type="fig"}). The most common reason for exclusion was a lack of multivariate analysis (n=55; including 19 randomised controlled trials (RCTs)), followed by studies that were not primary research (n=48). Studies which did not examine relapse (n=22) and those which had a partially or wholly inpatient population (n=20) were also excluded. A minority of studies (n=23) were excluded for various other reasons, such as the involvement of paediatric populations, or patient presentation to the ED was not due to acute asthma. A full list of excluded studies is available on request.

![PRISMA flow diagram illustrating the overview of the systematic literature search.](bmjresp2016000169f01){#BMJRESP2016000169F1}

Study characteristics {#s3b}
---------------------

Five prospective cohort studies,[@R22] [@R26] [@R28] two retrospective cohort studies,[@R29] [@R30] two administrative data analyses[@R31] [@R32] and one RCT[@R33] were included ([table 1](#BMJRESP2016000169TB1){ref-type="table"}). Apart from one study,[@R30] all included studies were conducted in North America.[@R22] [@R26] [@R28] [@R29] [@R31] Similarly, aside from one abstract, all other included studies were published peer-reviewed articles.[@R29] One study performed its multivariate analysis based on 8-week relapse proportions.[@R24] Demographic characteristics of included studies are displayed in [table 2](#BMJRESP2016000169TB2){ref-type="table"}. Note that ED management was left to the discretion of the treating physician in all studies but one,[@R24] which outlined a specific protocol. The definition of relapse was commonly given as some variant of 'any urgent medical treatment for asthma, regardless of location of care', except for two studies[@R30] [@R32] that restricted their relapses to those presenting back to the ED.

###### 

Descriptive characteristics of studies selected for inclusion in the review

  Author               Year of publication   Country     Study design                  Study period   Sample size   Relapse proportion (at 2 weeks)
  -------------------- --------------------- ----------- ----------------------------- -------------- ------------- ---------------------------------
  Rowe[@R33]           2007                  Canada      Randomised controlled trial   --             137           12.40%
  McCarren[@R24]       1998                  USA         Prospective cohort            1992--1995     284           10%
  Emerman[@R26]        1999                  USA         Prospective cohort            1996--1997     641           17%
  Singh[@R28]          1999                  USA         Prospective cohort            1996--1997     1228          15.80%
  Rowe[@R22]           2008                  Canada      Prospective cohort            2004--2005     695           13.90%
  Rowe[@R23]           2015                  Canada      Prospective cohort            2003--2007     807           14%
  Lin[@R29]            2009                  Canada      Retrospective cohort          2006--2007     257           --
  Prabhakaran[@R30]    2013                  Singapore   Retrospective cohort          2008--2009     1303          7.4% (4 week)
  Baibergenova[@R31]   2006                  Canada      Administrative database       2003--2004     23 253        --
  Withy[@R32]          2008                  USA         Administrative database       1999--2004     4318          4%

###### 

Select demographic characteristics of studies included in the review

                       Age (mean)      Female (%)   COPD status   Discharge medication                                      Race (largest proportion)   Current smoking (%)   Insurance (public/private)   Hospitalisation       Previous intubation (%)   ICS usage (%)
  -------------------- --------------- ------------ ------------- --------------------------------------------------------- --------------------------- --------------------- ---------------------------- --------------------- ------------------------- ---------------
  Rowe[@R33] (2007)    30±10           59           NA            Prednisone, β-agonist, ICS ± LABA                         NA                          39                    NA                           68% ever              7                         47
  McCarren[@R24]       35±10           40           Excluded      9--11 days of prednisone, theophylline, steroid inhaler   87% black                   37                    NA                           46% in past year      NA                        NA
  Emerman[@R26]        34±10           69           Excluded      5--7 days of prednisone + EP discretion                   49% black                   30                    74%                          26% in past year      13                        41
  Singh[@R28]          36±10           64           3%            67% received steroids                                     54% black                   35                    70%                          62% ever              17                        43
  Rowe[@R22] (2008)    29±10           64           Excluded      5--7 days of prednisone + EP discretion                   87% white                   39                    72%                          20% in past 2 years   8                         52
  Rowe[@R23] (2015)    30 (24--39)\*   58           Excluded      5--7 days of prednisone + EP discretion                   85% white                   33                    50% (medication coverage)    24% in past 2 years   7                         68
  Lin[@R29]            NA              NA           NA            NA                                                        NA                          NA                    NA                           NA                    NA                        NA
  Prabhakaran[@R30]    36±16           48           Excluded      ± prednisolone (79%), ICS                                 37% Chinese                 NA                    NA                           NA                    NA                        NA
  Baibergenova[@R31]   NA              62           NA            NA                                                        NA                          NA                    NA                           NA                    NA                        NA
  Withy[@R32]          NA              54           NA            NA                                                        NA                          NA                    100%                         NA                    NA                        NA

\*Median (IQR).

COPD, chronic obstructive pulmonary disease; EP, emergency physician; ICS, inhaled corticosteroids; LABA, long-acting β-agonists; NA, not available.

Quality assessment {#s3c}
------------------

All included observational studies had a relatively low risk of bias according to the NOS. Two studies[@R26] [@R28] scored seven out of eight possible points because their loss to follow-up was \>20%. All the remaining studies scored the full eight points (k=0.73). The included RCT had low risk of bias according to the RoB Tool.

Primary outcomes {#s3d}
----------------

### Relapse proportions {#s3d1}

One RCT[@R33] and seven observational studies[@R22] [@R26] [@R28] [@R30] [@R32] [@R33] reported the proportion of patients experiencing relapse after management and discharge for acute asthma. The authors of the two[@R29] [@R31] studies that failed to report their relapse proportions were contacted; however, in both cases, additional information was not obtained. Relapse proportions were recorded at 1 week,[@R22][@R24] [@R26] [@R32] [@R33] 2 weeks[@R22] [@R26] [@R28] [@R32] [@R33] and 4 weeks.[@R23] [@R24] [@R30] The relapse proportion at 2 weeks ranged from 4%[@R31] to 17%.[@R26] When 2-week and 4***-***week relapse proportions were examined based on the studies\' last year of data collection, there were slightly lower relapse rates in recent years ([figure 2](#BMJRESP2016000169F2){ref-type="fig"}). Six studies tracked relapse proportions at multiple postdischarge durations.[@R22][@R24] [@R26] [@R32] [@R33] All six studies had the greatest proportion of relapses occurring within the first week, with a median of 61% (IQR: 50--68) of all relapses occurring during week one. After this early peak, relapse proportions appear to increase at a relatively linear rate between weeks 1 and 4 ([figure 3](#BMJRESP2016000169F3){ref-type="fig"}). Median relapses were 8% at 1 week, 14% at 2 weeks, and 17% at 4 weeks ([figure 3](#BMJRESP2016000169F3){ref-type="fig"}).

![Proportion of patients experiencing relapse relative to the year when the data were collected.](bmjresp2016000169f02){#BMJRESP2016000169F2}

![Reported relapse rates at varying time periods after discharge from ED. Medians displayed with lines. Distinct studies represented by different colours. ED, emergency department.](bmjresp2016000169f03){#BMJRESP2016000169F3}

### Factors significantly associated with relapse {#s3d2}

Although 19 RCT studies underwent a full-text review, only one paper was included.[@R33] There were two studies which reported performing multivariate analyses, but the results were not presented.[@R34] [@R35] In the included RCT, there were three factors identified as significant on multivariate analysis: ICS use prior to ED presentation, prior intubation and female sex. The strongest association identified in the RCT was female sex (HR=7.2; 95% CI 2.3 to 23.1).

Factors commonly and significantly associated with relapse occurrence within 4 weeks of ED discharge in observational studies included: patient sex, previous healthcare usage, symptom duration and ICS usage at ED presentation ([table 3](#BMJRESP2016000169TB3){ref-type="table"}). The most commonly investigated variable was female sex; from models reported in six studies,[@R22] [@R23] [@R28] [@R31] five reported a significant finding with aOR ranging from 1.17 (95% CI 1.03 to 1.34) to 7.2 (95% CI 2.3 to 23.1) ([figure 4](#BMJRESP2016000169F4){ref-type="fig"}).

###### 

Factors significantly (p\<0.05) associated, on multivariate analysis, with asthma relapse within 4 weeks of ED treatment (✓), factors studied but not found to be significant (ø) and factors not assessed (NA)

                          Rowe 2007              Emerman 1999          Singh 1999   Rowe 2008                Rowe 2015             Lin 2009   Prabhakaran 2013        Baibergenova 2006        Withy 2008
  ----------------------- ---------------------- --------------------- ------------ ------------------------ --------------------- ---------- ----------------------- ------------------------ ------------------------
  Female sex              ✓ (7.2, 2.3 to 23.1)   NA                    ø            ✓ (1.57, 1.14 to 2.09)   ✓ (1.9, 1.2 to 3.0)   NA         NA                      ✓ (1.23, 1.10 to 1.37)   ✓ (1.17, 1.03 to 1.34)
  Older age               ø                      NA                    NA           ø                        ø                     NA         ✓ (0.98, 0.97 to 1.0)   ✓ (0.81, 0.69 to 0.94)   Ø
  Past healthcare usage   NA                     ✓ (1.3, 1.1 to 1.5)   NA           ✓ (1.47, 1.18 to 1.80)   ø                     ø          NA                      NA                       NA
  Severity                NA                     NA                    NA           ø                        ø                     ø          NA                      ✓ (2.51, 1.12 to 5.62)   NA
  Symptom duration        NA                     ✓ (2.5, 1.2 to 5.2)   NA           ø                        ✓ (1.7, 1.3 to 2.3)   NA         NA                      NA                       NA
  ICS at presentation     ✓ (3.1, 1.0 to 9.8)    NA                    NA           ✓ (1.39, 1.07 to 1.78)   ✓ (1.9, 1.1 to 3.2)   NA         NA                      NA                       NA
  Cost/insurance          NA                     NA                    NA           ø                        ø                     NA         NA                      NA                       ✓ (1.15, 1.0 to 1.32)

ED, emergency department; ICS, inhaled corticosteroids.

![Adjusted ORs for female sex acting as a predictor for acute asthma relapse after ED treatment and discharge. ED, emergency department.](bmjresp2016000169f04){#BMJRESP2016000169F4}

Healthcare usage included subcategories ([table 3](#BMJRESP2016000169TB3){ref-type="table"}) for ED asthma visits such as: visits that occurred in the past 6 months,[@R24] 1 year,[@R26] and 2 years,[@R22] past urgent clinic visits for asthma[@R26] and prior hospitalisations for asthma.[@R22] Severity at ED presentation was assessed using the Canadian Triage and Acuity Scale (CTAS) score of one.[@R30] Symptom duration was assessed either directly by asking patients to report the length of their symptoms,[@R23] [@R26] or indirectly by asking how long they had been experiencing difficulty with activities or work.[@R24] Symptoms present for over 24 hours had a relatively strong association with relapse, and had an aOR consistently above 1.5 (range: aOR: 1.7 (95% CI: 1.3 to 2.3) to aOR: 2.5 (95% CI: 1.2 to 5.2)). ICS usage (including ICS/LABA combination) at presentation had consistently positive associations with relapse (range: aOR: 1.39 (95% CI: 1.07 to 1.78) to aOR: 3.1 (95% CI: 1.0 to 9.8)).[@R22] [@R23] Increasing age, either by unit increase (aOR=0.98; 95% CI 0.97 to 1.0) or by age categories (eg, ages 46--55; aOR=0.81; 95% CI 0.69 to 0.94), was the only factor associated with a lower likelihood of relapse in more than one study.[@R30] [@R31]

Secondary outcomes {#s3e}
------------------

### Time between ED discharge and relapse {#s3e1}

One study reported that the median time to relapse was 9 days (IQR: 3--19);[@R30] however, no other studies reported this outcome.

### Medical management {#s3e2}

Four studies[@R22] reported that the proportion of patients arriving with a recent history of SCS use ranged from 2% to 23%. Similarly, five studies tracked those patients receiving SCS after ED discharge[@R22] [@R23] [@R26] [@R30] [@R33] as ranging from 63% to 100%. Proportions of patients using ICS at ED presentation[@R22] [@R23] [@R26] [@R28] [@R33] and those prescribed ICS at discharge[@R22] [@R23] [@R30] [@R33] varied widely among studies with ranges of 35--82% and 29--100%, respectively. ICS/LABA usage at presentation was reported by three studies[@R22] [@R23] [@R33] and was relatively consistent with a range from 32--33%. Short-acting β~2~-agonist use before presentation was much more uniform (82--87%).[@R22] [@R23] [@R26] [@R28] [@R33]

Discussion {#s4}
==========

This comprehensive systematic review identified 10 studies involving 32 923 patients that performed multivariate analysis to investigate factors associated with relapse after treatment for adult patients seen with acute asthma in the ED setting. Quality assessment showed that all included studies were of high methodological quality, which strengthens the validity of these results. Given the variations in models used to generate aORs and in the factors reported, results were not pooled in a traditional meta-analysis. Overall, there is strong evidence that women and patients on pre-existing ICS therapy are more likely to relapse, and perhaps should be managed more aggressively.

Relapse proportions were notably high within the first week in most of the studies which reinforces the need for primary care providers to see patients early after discharge to reassess response to therapy, adjust management and provide additional recommendations.[@R11] Apart from two studies, relapses were relatively consistent across the included studies: one that reported relapse proportions of 4% at 2 weeks[@R32] and another that reported 7.4% at 4 weeks.[@R30] These two studies restricted their outcomes to patients relapsing to EDs and that may have influenced the estimates; all other studies provided patient-reported relapse outcomes involving multiple potential treatment location. In both studies,[@R30] [@R32] a large number (44.8% and 46.0%, respectively) of patients had outpatient follow-up arranged prior to discharge to address asthma symptoms, and this is a possible contributor to the significantly reduced proportion of patients relapsing. The author of the second study[@R30] (based in Singapore and the only study included in this review that originated outside North America) acknowledged that the reported relapse proportions were lower than expected potentially due to differences in healthcare delivery relative to North America. One such difference is a higher availability of after-hours, or 24-hour, primary care.[@R36] Given the relative recency of these two studies, they are potentially overstating the recent relapse reduction shown in [figure 2](#BMJRESP2016000169F2){ref-type="fig"}; despite this, there is some evidence that the number of patients receiving guideline-recommended care in EDs has been increasing over recent years, leading to improved outcomes.[@R13]

It is important to highlight the large number of relapses occurring within the first few days after ED discharge. Nearly two-thirds of patients experiencing relapse do so within the first week and this appears to be an area where improved ED management, and perhaps strategies to prompt primary care follow-up, could improve outcomes.[@R35]

Many of the factors significantly associated with relapse risk on multivariate analysis make intuitive sense. Female sex is a predisposing factor for severe asthma[@R37] and women have been shown to perceive symptoms differently, so it is perhaps not surprising that this review finds that female sex was also associated with more frequent relapses following ED visits for acute asthma. Logic predicts that patients with past tendencies to use the ED will not hesitate to return; likewise, patients who are experiencing unrelenting symptoms over a longer duration may be struggling with self-management of their asthma, or have more severe baseline disease, and may need urgent care. Indeed, lack of symptom improvement has been identified as a common cause for patients with asthma to seek urgent care.[@R7] Although infrequently examined by these studies, medication cost and patient insurance certainly impact treatment efficacy, especially when we consider that up to 37% of patients will not fill their prescriptions after an asthma exacerbation.[@R38] It was encouraging that results were directionally concurrent; in other words, there were no factors *associated* with relapse that were found to *reduce* relapse among the included studies.

Studies discussing asthma relapse are common in the medical literature; however, no similar systematic reviews were identified in our searches. In addition, while most guidelines do make mention of factors associated with relapse, the vast majority are not evidence-based and nor do they provide recommendations on how to use these factors in practice. For example, the most recent guideline from the GINA[@R11] focused on medical management to prevent asthma relapse, provided no summary of factors associated with relapse, and failed to guide clinicians regarding which high-risk patients to target. In a similar vein, the National Review on Asthma Deaths (NRAD) in 2015 identified that 10% of asthma deaths in the UK occur within 28 days of discharge from the ED.[@R39] The authors state that there is a need for health professionals to 'be aware of the factors that increase the risk of asthma attacks', without explicitly stating what those factors are.

Factors which could practically be screened to provide the most benefit would include female sex, previous ICS usage and healthcare resource usage. Identifying patients with these traits and targeting them for more explicit discharge planning and rigorous outpatient follow-up might mitigate the severity and frequency of relapses. Options might include the identification of care gaps that may be influencing their asthma attacks (ie, improper inhaler techniques, non-adherence to medication, lack of education), *stepping up* their preventer medication (ie, adding ICS to those ICS naïve at presentation[@R15] or switching from ICS to ICS/LABA[@R33]), providing the medications in the ED rather than the prescriptions or directing strategies from the ED to ensure that patients have close follow-up with a primary care provider for monitoring of symptoms, adjustment on medication and consideration of referrals.

Strengths and limitations {#s5}
=========================

There are several potential limitations to this review that require discussion. First, high-quality evidence in this field is limited and this review included a variety of prospective designs (eg, RCTs and cohorts), which was an important a priori decision. To be reported in the factors associated with relapses, all prospective studies needed to report an adjusted analysis. Second, data collected from patient interviews may be subject to recall bias. With a few exceptions,[@R22] [@R23] data were collected using slightly different interview questions, necessitating some grouping based on author discretion. In addition, differential loss to follow-up or incomplete outcome data in the included studies may have introduced attrition bias. Third, owing to the relatively small number of included studies and overall small sample size, we were unable to formally assess the potential for publication bias; however, comprehensive searches of grey and published literature were performed without restrictions on language, dates or publication status, so it is unlikely that many studies were missed. Fourth, the ORs of non-significant factors from multivariable analyses were not reported in most papers, which may over-represent the influence of some factors. Finally, selection bias is always a concern in systematic reviews; however, two independent reviewers with a separate third-party adjudicator were used throughout all stages of the review in order to minimise selection bias and ensure consistency.

Conclusion {#s6}
==========

Reducing relapses after treatment for acute asthma represents a potential improvement in the quality of life for patients with asthma and a reducible strain on crowded EDs. Moreover, they present an opportunity to improve outcomes for patients while reducing direct healthcare costs. Practical factors associated with relapse occurrence within 4 weeks of ED discharge have been identified, which may help to stratify patients based on their risks and potentially influence disposition decisions. Further research should focus on strategies to decrease relapses using validated clinical decision rules in order to identify patients at high risk for relapse after discharge, optimise their management and improve outcomes.
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